Ancora Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDA

Beacon Pointe Advisors LLC purchased a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRT

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.32% on

Nvidia revenue more than doubles, Okta and Veeva climb on beats, and more

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced manageme

EP Wealth Advisors LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) du

Advisors Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals Incorpo

Allworth Financial LP acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) dur

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked ServiceNow, Inc.

CNBC's Halftime Report Final Trades: Sechan picked ServiceNow (NYSE: NOW), Lebenthal chose Verte

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma

Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. How

AssuredPartners Investment Advisors LLC purchased a new position in shares of Vertex Pharmaceuticals

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swic

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Vertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area. The company

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 5.35% on

I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Bu

Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight an

Its sales rose at a double-digit rate; net profit growth was more modest. There's another developmen

TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees gr

Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch str

Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Over

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript

Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over yea

Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billio

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the an

U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams C

CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon u

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refin

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on a

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the

Truist Securities analyst Danielle Brill maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Bu

The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperfo

Vertex to acquire Crinetics for $10 billion, adding approved acromegaly drug Palsonify and late-stag

Baird analyst Brian Skorney maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform an

Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vert

Crinetics Pharmaceuticals shares are trading higher in Monday's after-hours session after the co

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX),

Vertex Pharmaceuticals today announced that it has signed a Letter of Intent (LOI) with the pan-Cana

FDA expands Vertex Casgevy label to patients aged 2 and older, making about 5,500 more U.S. children

- First and only approved genetic therapy to treat children as young as 2 years for both severe sick

https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-s

Jim Lebenthal recommends Vertex Pharmaceuticals in the healthcare sector. Jenny Van Leeuwen picks Ve

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 8.53% on a

Vertex Reports CASGEVY Data Showing Sustained Benefits In Children With Sickle Cell Disease And Beta